We evaluated the immunogenecity of the recombinant HBV Cuban vaccine, utilising the 012 months scheme in children between 1 to 10 years of age. Whith the second dose, 98% of after the vaccinated children developed seroprotection (values 210 IU/l) and after the third dose (75 days), 100% had antibody levels > 100 IU/l.
